Protocol Ledger

NCT03736447 · Phase III · COMPLETED

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

Interventional Phase III clinical trial protocol NCT03736447 sponsored by Aimmune Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-27 Enrollment: 146 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03736447
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)146 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03736447
Protocol FieldVerified Registry Value
NCT IdentifierNCT03736447
Consolidated Lead SponsorAimmune Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment146 participants (ACTUAL)
Registered Start Date2018-12-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI